RxDoctor Payments Data

Gregory Heumann, MD

Internal Medicine · North Vernon, INNPI 1346213790

Payments from drug & device makers

$353in general payments, 2019–2025

Across 17 payments — averaging $20.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sensible Medical Innovations Inc$106
  • Amgen$47
  • E.r. Squibb & Sons, L.L.C.$46
  • Novartis$29
  • Lilly USA, LLC$28
  • Amarin Pharma, Inc.$27
  • plus $70 from 4 others

What the payments were for

  • Food & beverage$30787%
  • Education$4613%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$353 in reported general payments places this provider in the 60th percentile of 1,747 internal medicine providers in Indiana.

See all internal medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$10,070
Medicare patients
105
Services billed
198

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin40$63,092
XareltoRivaroxaban68$55,767
EliquisApixaban56$54,181
TrulicityDulaglutide37$51,382
GlyxambiEmpagliflozin/Linagliptin18$28,353
TradjentaLinagliptin31$25,829
Spiriva HandihalerTiotropium Bromide19$14,484
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$14,459
LinzessLinaclotide15$11,980
FarxigaDapagliflozin Propanediol14$11,592
JanuviaSitagliptin Phosphate14$10,135
Breo ElliptaFluticasone/Vilanterol16$7,382
Lantus SolostarInsulin Glargine,hum.Rec.Anlog34$5,796
ArexvyRsvpref3 Antigen/As01e/Pf12$3,834
Albuterol Sulfate HfaAlbuterol Sulfate124$3,412

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$26$55,76768 claims
Lilly USA, LLCTrulicity$28$51,38237 claims
AstraZenecaFarxiga$12$11,59214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,747 internal medicine providers in Indiana.

Other internal medicine in North Vernon

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →